Nuclear Medicine or Radiopharmaceuticals MarketGlobal Trends, Market Share, Industry Size, Growth, Opportunities, and Market Forecast 2019 to 2026
Global Nuclear Medicine/Radiopharmaceuticals Market is estimated to value over USD 6.1 billion by 2026 end and register a CAGR of over 4.9% during the forecast period 2019 to 2026.
It is to be observed
that factors such as the rise of applications in radioisotopes, substantial
public awareness, imaging devices, a large volume of radiopharmaceuticals and a
cancer treatment that is based on alpha therapy, are all reasons which helped to
revitalise the global nuclear medicine/radiopharmaceuticals market growth.
Furthermore, market analysis shows that the manufacture of radiopharmaceuticals
with the help of cyclotrons, increasing requirements in the emerging markets,
and opting for the latest methods as opposed to the traditional equipment have
helped in expanding the global nuclear medicine/radiopharmaceuticals market
size.
Radiopharmaceuticals
are constituted by radioactive isotopes which comprise of applications in
therapeutics and diagnosis. They contain a substance which is radioactive and
is used in treatments such as cardiac, cancer and neurological disorders. These
therapeutic radiopharmaceuticals serve as a more convenient option for
illnesses such as cancer and oncology treatment. In fact, it is a far safer
option for patients as opposed to X-rays and other imaging techniques.
Technological
innovations in imaging has posed many shifts and changes with the arrival of
hybrid technology namely, the single photon emission computed tomography
(SPECT) and positron emission tomography (PET). A far more accurate and precise
diagnosis can be made possible with the aid of imaging, along with a heightened
attenuation correction, specificity and localization. To add to this, SPECT has
made many strides in avenues such as thyroid imaging, cardiology, cancer
diagnosis and spleen/liver imaging. In the case of PET, also known as hybrid
imaging, radiopharmaceuticals such as 18F-fluorodeoxyglucose (18F-FDG). This is
used extensively in PET diagnosis.
The nuclear
medicine/radiopharmaceuticals market is projected to expand, primarily, due to
alpha radioimmunotherapy involved treatment, a strong presence of chronic
diseases and innovations in imaging techniques that involves the use of
radiopharmaceuticals. All these factors combined, have been instrumental in
boosting the market growth of the pharmaceuticals industry. However, there are
certain hindrances owing to the lack of availability of substitutes in the
radiopharmaceuticals, stringent regulations in clinical investigations and
translational methodologies, scarcity in reimbursement, as well as the short
life span associated with the radiopharmaceuticals. Such hindrances, will most
likely, pose negative impacts on the global nuclear medicine/radiopharmaceuticals
market potential during the forecast time frame.
Some of the players
operating in the global radiopharmaceuticals and nuclear medicine market
includes Lantheus Medical Imaging Inc., Eczacibasi-Monrol Nuclear
Products, GE Healthcare, IBA Molecular Imaging, Bayer Healthcare, Nordion Inc,
Bracco Imaging S.p.A, Advanced Accelerator Applications S.A., Cardinal Health
Inc.
Request a Sample
Report @ https://www.futurewiseresearch.com/request-sample.aspx?id=3463&page=requestsample
Nuclear
Medicine/ Radiopharmaceutical Market Segmentation:
By
Type
- Diagnostic Nuclear Medicine
- Spect Radiopharmaceuticals
~ Tc-99m
~ Tl-201
~ Ga-67
~ I-123
~ Other Spect Isotopes
- Pet Radiopharmaceuticals
~ F-18
~ Ru-82
~ Other Pet Isotopes
- Therapeutic Nuclear Medicine
- Alpha Emitters
~ Ra-223
- Beta Emitters
~ I-131
~ Y-90
~ Sm-153
~ Re-186
~ Lu-177
~ Other Beta Emitters
- Brachytherapy Isotopes
~ I-125
~ Ir-192
~ Pd-103
~ Cs-131
~ Other Brachytherapy Isotopes
By
Application
- Diagnostic Applications
- Spect Applications
- Cardiology
- Lymphoma
- Neurology
- Thyroid
- Other Spect Applications
- Pet Applications
- Oncology
- Cardiology
- Neurology
- Other Pet Applications
- Therapeutic Applications
- Thyroid
- Bone Metastasis
- Lymphoma
- Endocrine Tumors
- Other Therapeutic Applications
By
Procedural Volume
- Diagnostic Procedures
- Spect Radiopharmaceuticals
- Pet Radiopharmaceuticals
- Therapeutic Procedures
- Beta Emitters
- Alpha Emitters
- Brachytherapy Isotopes
By
Region
- Europe
- North America
- Asia Pacific
- Rest of the World
Purchase
a Copy & Ask For Discount: https://www.futurewiseresearch.com/request-sample.aspx?id=3463&page=askfordiscount
FutureWise
Key Takeaways:
- Growth prospects
- SWOT analysis
- Key trends
- Key data-points affecting
market growth
Objectives
of the Study:
- To provide with an exhaustive analysis on the
global nuclear medicine/pharmaceuticals market by type, by
application, by procedural volume and by region
- To cater comprehensive information on factors
impacting market growth (drivers, restraints, industry-specific restraints
and opportunities)
- To forecast and evaluate micro-markets and the
overall market
- To predict the market size, in key regions (along
with countries)— North America, Europe, Asia Pacific and the rest of the
world
- To record, evaluate and analyze competitive
landscape mapping- technological advancements, product launches,
expansions and mergers
We
specialise in high-growth niche markets, assuring flexibility, agility and
customised solutions for our clients. Through in-depth market insights and
consultancy, we present our clients with the tools they need to be at the
forefront of their industry – a position secured for far more than the near
future.
Contact Us:
Company
Name: FutureWise Research
Contact Person: Vinay Thaploo
Email: sales@futurewiseresearch.com
Phone: +44 141 628 9353 / +1 970 279 4295
City: Leeds
Country: United Kingdom
Website: www.futurewiseresearch.com
Contact Person: Vinay Thaploo
Email: sales@futurewiseresearch.com
Phone: +44 141 628 9353 / +1 970 279 4295
City: Leeds
Country: United Kingdom
Website: www.futurewiseresearch.com
Comments
Post a Comment